A breakthrough in diagnostic testing is providing hope for patients like Enisa, who is receiving new targeted treatment to combat HER2-low breast cancer.
Guests Lorraine Tyler, an advocate and lung cancer patient, and Mark Brooke, CEO of Lung Foundation Australia, explore the importance of biomarker testing in lung cancer.
Biomarkers play a crucial role in Roche’s commitment to personalised healthcare. To find them, we rely on the promising research of our external partners.